Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gene therapy company bluebird bio acquires Precision Genome Engineering

Executive Summary

Bluebird bio Inc. (gene therapy for genetic and orphan diseases) acquired Precision Genome Engineering Inc. (aka Pregenen; gene editing and cell signaling technologies) for 408.7k bluebird shares up front plus 94.1k shares held back for 18 months (together worth $19.2mm), and the assumption of $4.9mm of current liabilities.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies